Third, we used this variant in drug-target MR tests as a genetic predictor for therapeutically altered EPO levels to help inform the long-term effects of elevated endogenous EPO levels on risk of cardiovascular disease (CVD) or clinical markers (blood pressure and resting heart rate) predisposing to CVD risk factors (e.g., hypertension). The gene discussed is EPO; the disease is cardiovascular disorder.